Owlstone Medical Ltd

Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive diagnostics for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in health care costs.

The company’s microchip FAIMS (Field Asymmetric Ion Mobility Spectrometer) sensor is a platform technology that can be programmed in software to detect targeted biomarkers of disease in breath (and other bodily fluids). FAIMS can be used in clinical diagnostics and precision medicine with application in cancer and a wide range of other medical conditions. Highly sensitive and selective, these tests allow for early diagnosis when treatments are more effective and where more lives can be saved.

Owlstone Medical is currently developing tests for lung and colorectal cancer, two of the most common cancer killers worldwide, and for asthma stratification by therapeutic response. The company also sells R&D tools and services to academic, clinical and pharma partners who want to develop breath based diagnostics for their own applications.

Address

Owlstone Medical Ltd
162, Cambridge Science Park
Milton Road, Cambridge
Cambridgeshire, United Kingdom
CB4 0GD
Telephone: +44 (0)1223 428200
Fax: +44 (0)1223 428201
Web: http://www.owlstone.co.uk

Current Job Vacancies

Recent News from Owlstone Medical Ltd